These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 12183667

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.
    Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA.
    J Hypertens; 2001 Mar; 19(3):465-73. PubMed ID: 11288817
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.
    Nap A, Balt JC, Pfaffendorf M, Van Zwieten PA.
    J Hypertens; 2002 Sep; 20(9):1821-8. PubMed ID: 12195125
    [Abstract] [Full Text] [Related]

  • 6. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, Sjöquist PO, Abrahamsson T.
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
    Belz GG, Butzer R, Kober S, Mutschler E.
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
    Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K, Naka T.
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y, Naka T.
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [Abstract] [Full Text] [Related]

  • 12. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K.
    Cardiovasc Res; 2006 Oct 01; 72(1):184-90. PubMed ID: 16938288
    [Abstract] [Full Text] [Related]

  • 13. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.
    Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, Nishikawa K.
    Eur J Pharmacol; 1997 Jan 14; 319(1):137-46. PubMed ID: 9030909
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
    Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N, Vauquelin G.
    Br J Pharmacol; 1999 Feb 14; 126(4):1057-65. PubMed ID: 10193788
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.